Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Symptomatic Sickle Cell Disease
NCT03263559Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Oct 2017
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxyurea, antithymocyte globulin rabbit, thiotepa, fludarabine, cyclophosphamide and 1 more in sickle cell disease (SCD), sponsored by Medical College of Wisconsin. Primary endpoint: Event Free Survival at 2 years. Started Oct 2017; status: completed.
02
Drugs
hydroxyureaantithymocyte globulin rabbitthiotepafludarabinecyclophosphamide
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03263559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03263559.